ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Cytomeglovirus"

  • 2022 American Transplant Congress

    Recurrent Cytomegalovirus and the Role of Secondary Prophylaxis in Heart and Lung Transplant Recipients

    S. N. Finder1, K. Harrison1, M. Morrison1, S. Rega2, I. Feurer2, C. Gorsline3, G. Satyanarayana3, S. Hamel1

    1Department of Pharmaceutical Sciences, Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt Transplant Center, Nashville, TN, 3Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN

    *Purpose: This study aimed to describe the incidence of cytomegalovirus (CMV) recurrence in heart and lung transplant recipients and the effect of secondary prophylaxis (SP)…
  • 2022 American Transplant Congress

    Valganciclovir for the Prevention of CMV After Treatment of Rejection with Anti-Lymphocyte Depleting Antibodies in Kidney Transplant Recipients

    M. Mahoney, J. Nelson, E. Kincaide, R. Hall, H. Sweiss

    University Health, San Antonio, TX

    *Purpose: To evaluate efficacy and safety of valganciclovir for prevention of cytomegalovirus (CMV) after treatment of rejection with anti-lymphocyte depleting antibodies (ALA).*Methods: This single-center retrospective…
  • 2022 American Transplant Congress

    Detection of CMV Mediated Sub-Clinical Rejection by Urine Biomarkers

    S. Ghosh1, R. Sarwal1, C. Mark1, E. Reed2, J. Shoji3, S. Bunnapradist2, T. Sigdel3, M. Sarwal3

    1Nephrosant Inc, San Francisco, CA, 2UCLA, Los Angeles, CA, 3UCSF, San Francisco, CA

    *Purpose: Research on early detection of Cytomegalovirus (CMV) mediated sub-clinical rejection (sAR) is in its nascence. This study explores the efficacy of urine-based biomarkers for…
  • 2022 American Transplant Congress

    Avoiding Cytomegalovirus Mismatching in Deceased Donor Kidney Allocation System in the US

    B. Tanriover1, B. Sandikci2, Y. Ulukus3, M. A. Ergun2, V. K. Ariyamuthu1, M. Al-Obaidi4, T. Zangeneh4

    1Division of Nephrology, The University of Arizona, Tucson, AZ, 2Department of Industrial Engineering, Istanbul Technical University, Istanbul, Turkey, 3Department of industrial Engineering, Istanbul Technical University, Istanbul, Turkey, 4Division of Infectious Disease, The University of Arizona, Tucson, AZ

    *Purpose: Cytomegalovirus (CMV) mismatch, donor-positive/recipient-negative serostatus (D+/R-), carries a high risk of developing CMV infection, graft failure mortality. The current kidney allocation system (KAS) does…
  • 2022 American Transplant Congress

    Seasonal Variation of Cytomegalovirus Infection in Kidney Transplant Recipients

    M. Jorgenson, B. Astor, C. Saddler, J. Smith, F. Aziz, D. Mandelbrot, N. Garg

    University of Wisconsin Health, Madison, WI

    *Purpose: Studies conducted in the northern United States found cytomegalovirus (CMV) disease after liver transplantation follows a seasonal pattern, with increased incidence in Fall and…
  • 2022 American Transplant Congress

    Preemptive Therapy in Cytomegalovirus (CMV) Seropositive Donor to Seronegative Recipient Liver Transplants

    J. Revollo, E. Aldag, K. Cooper, B. Noell, V. Casingal, K. Gajurel

    Transplant, Atrium Health's Carolinas Medical Center, Charlotte, NC

    *Purpose: To evaluate if a preemptive therapy strategy can prevent CMV disease and induce CMV seroconversion.*Methods: Observational data collection for CMV D+/R- adult liver transplant…
  • 2022 American Transplant Congress

    Maribavir (MBV) versus Investigator-Assigned Therapy (IAT) for Refractory Cytomegalovirus (CMV) Infection (with or without Resistance) in Solid Organ Transplant (SOT) Recipients: Subgroup Safety Analysis of a Phase 3 Study

    R. M. La Hoz1, D. Florescu2, D. Kumar3, F. Saliba4, J. Gu5, A. Sundberg5

    1Univ. Texas Southwestern Medical Center, Dallas, TX, 2Univ. Nebraska Medical Center, Omaha, NE, 3Univ. Health Network, Toronto, ON, Canada, 4Univ. Paris Saclay, Paris, France, 5Takeda Development Center Americas, Inc., Lexington, MA

    *Purpose: In a Phase 3 study of MBV vs IAT (val/ganciclovir, foscarnet, or cidofovir) for refractory CMV infection (with/without resistance; R/R) in hematopoietic cell transplant…
  • 2022 American Transplant Congress

    Incidence and Outcomes of CMV Infection in Pancreas Transplant with Thymoglobulin Induction: A Single Center Experience

    W. Abusalah, A. Yadav

    Thomas Jefferson University Hospital, Philadelphia, PA

    *Purpose: CMV infection is a major infectious complication in pancreas transplant recipients (PTR). Incidence of CMV viremia in PTR with thymoglobulin induction and it's effect…
  • 2022 American Transplant Congress

    Letermovir for Prophylaxis of Cytomegalovirus After Solid Organ Transplantation: A Single-Center, Observational Study

    T. N. Bullard1, C. A. Moore2, J. Dasigi2, L. M. Sacha2, C. A. Iasella3, K. A. Shimko2, E. K. McCreary4, F. P. Silveira4

    1Massachusetts General Hospital, Boston, MA, 2UPMC, Pittsburgh, PA, 3Univ of Pittsburgh, Pittsburgh, PA, 4Univ of Pittsburgh and UPMC, Pittsburgh, PA

    *Purpose: Cytomegalovirus (CMV) infections cause significant complications post-transplant; however, prophylactic medications are often limited by toxicities. Letermovir is a novel terminase inhibitor specific to CMV…
  • 2022 American Transplant Congress

    An Interventional Study Using Cell-Mediated Immunity to Guide Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multi-Center Study

    J. T. Solera1, C. Cervera2, S. Hosseini1, J. Gill3, S. Shalhoub4, J. Zaltzman5, N. Pinzon1, A. Humar1, D. Kumar1

    1UHN, Toronto, ON, Canada, 2UAlberta, Edmonton, AB, Canada, 3UBC, Vancouver, BC, Canada, 4LHSC, London, ON, Canada, 5StMH, Toronto, ON, Canada

    *Purpose: There are limited interventional studies using CMV cell-mediated immunity to guide the duration of antiviral prophylaxis. We aimed to use CMV CMI to guide…
  • 1
  • 2
  • 3
  • …
  • 33
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences